剛剛,2024JCR正式發(fā)布!
![]()
CA-A CANCER JOURNAL FOR CLINICIANS的IF腰斬,但憑借232.4的高分仍然高居榜首。其次是兩本Nature綜述子刊。
國(guó)產(chǎn)期刊方面,Signal Transduction and Targeted Therapy以52.7的高分位居第一。
Nature和Science分別為48.5和45.8。
更多期刊請(qǐng)查看下表。
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
版權(quán)聲明
來(lái)源:學(xué)之策
特別聲明:以上內(nèi)容(如有圖片或視頻亦包括在內(nèi))為自媒體平臺(tái)“網(wǎng)易號(hào)”用戶上傳并發(fā)布,本平臺(tái)僅提供信息存儲(chǔ)服務(wù)。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.